Anti-inflammatory drugs reduce age-related decreases in brain volume in cognitively normal older adults

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 497-505

  Walther, K ^a   Bendlin, B B ^b,c   Glisky, E L ^a   Trouard, T P ^d   Lisse, J R ^e   Posever, J O ^f   Ryan, L ^a  

^a University of Arizona   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d University of Arizona   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f PHOENIX INDIAN MEDICAL CENTER   (United States)

Author keywords

Aging; Alzheimer's disease; Anti inflammatory agents; Magnetic resonance imaging; Voxel based morphometry

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; ROFECOXIB; SALAZOSULFAPYRIDINE; SALSALATE; STEROID; SULINDAC; VALDECOXIB;

ADULT; AGED; AGING; ARTHRITIS; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; FUSIFORM GYRUS; GRAY MATTER; HUMAN; IMAGE ANALYSIS; INFERIOR TEMPORAL GYRUS; INFLAMMATION; MESENCEPHALON; MIDDLE FRONTAL GYRUS; MIDDLE TEMPORAL GYRUS; NEUROPROTECTION; OCCIPITAL CORTEX; PAIN; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; PRIORITY JOURNAL; SUPERIOR FRONTAL GYRUS; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY; WHITE MATTER;

AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ARIZONA; ARTHRITIS; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED;

EID: 79952898339     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.03.006     Document Type: Article

References (43)

1. Lyketsos C.G., Breitner J.C., Green R.C., Martin B.K., Meinert C., Piantadosi S., Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808. ADAPT Research Group.
2. Aisen P.S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002, 1:279-284.
3. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
4. Aisen P.S., Schmeidler J., Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58:1050-1054.
5. Alexander G.E., Chen K., Merkley T.L., Reiman E.M., Caselli R.J., Aschenbrenner M., Santerre-Lemmon L., Lewis D.J., Pietrini P., Teipel S.J., Hampel H., Rapoport S.I., Moeller J.R. Regional network of magnetic resonance imaging gray matter volume in healthy aging. Neuroreport 2006, 17:951-956.
6. Arvanitakis Z., Grodstein F., Bienias J.L., Schneider J.A., Wilson R.S., Kelly J.F., Evans D.A., Bennett D.A. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008, 70:2219-2225.
7. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. NeuroImage 2000, 11:805-821.
8. Bartolini M., Candela M., Brugni M., Catena L., Mari F., Pomponio G., Provinciali L., Danieli G. Are behaviour and motor performances of rheumatoid arthritis patients influenced by subclinical cognitive impairments? A clinical and neuroimaging study. Clin. Exp. Rheumat. 2002, 20:491-497.
9. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 1995, 16:523-530.
10. Breitner J.C., Zandi P.P. Do nonsteroidal antiinflammatory drugs reduce the risk for Alzheimer's disease?. N. Engl. J. Med. 2001, 345:1567-1568.
11. Broe G.A., Grayson D.A., Creasey H.M., Waite L.M., Casey B.J., Bennett H.P., Brooks W.S., Halliday G.M. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 2000, 57:1586-1591.
12. Chetelat G., Landeau B., Eustache F., Mezenge F., Viader F., de la Sayette V., Desgranges B., Baron J.C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. NeuroImage 2005, 27:934-946.
13. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327:128.
14. Fliessbach K., Helmstaedter C., Urbach H., Althaus A., Pels H., Linnebank M., Juergens A., Glasmacher A., Schmidt-Wolf I.G., Klockgether T., Schlegel U. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005, 64:1184-1188.
15. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
16. Glisky E.L., Kong L.L. Do young and older adults rely on different processes in source memory tasks? A neuropsychological study. J. Exp. Psychol. Learn. Mem. Cogn. 2008, 34:809-822.
17. Godbout J.P., Johnson R.W. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Neurol. Clin. 2006, 24:521-538.
18. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 2001, 14:21-36.
19. Hayden K.M., Zandi P.P., Khachaturian A.S., Szekely C.A., Fotuhi M., Norton M.C., Tschanz J.T., Pieper C.F., Corcoran C., Lyketsos C.G., Breitner J.C., Welsh-Bohmer K.A. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007, 69:275-282.
20. Henderson A.S., Jorm A.F., Christensen H., Jacomb P.A., Korten A.E. Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatr. Psychiatry 1997, 12:926-930.
21. in't Veld B.A., Launer L.J., Hoes A.W., Ott A., Hofman A., Breteler M.M., Stricker B.H. NSAIDs and incident Alzheimer's disease. The Rotterdam study. Neurobiol. Aging 1998, 19:607-611.
22. in't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345:1515-1521.
23. Jofre-Monseny L., Minihane A.M., Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol. Nutr. Food Res. 2008, 52:131-145.
24. Lemaitre H., Crivello F., Dufouil C., Grassiot B., Tzourio C., Alperovitch A., Mazoyer B. No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. NeuroImage 2005, 24:1205-1213.
25. McGeer P.L., McGeer E.G., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990, 335:1037.
26. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
27. Mechelli A., Friston K.J., Frackowiak R.S., Price C.J. Structural covariance in the human cortex. J. Neurosci. 2005, 25:8303-8310.
28. Raz N., Rodrigue K.M. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci. Biobehav. Rev. 2006, 30:730-748.
29. Raz N., Rodrigue K.M., Acker J.D. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 2003, 117:1169-1180.
30. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8299-8302.
31. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., Baranak C.C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71. Rofecoxib Protocol 091 Study Group.
32. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999, 53:197-201.
33. Slotnick, S.D., 2008. Cluster_threshold. Retrieved December 10, 2008 from http://www2.bc.edu/~slotnics/scripts.htm.
34. Smith C.D., Chebrolu H., Wekstein D.R., Schmitt F.A., Markesbery W.R. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol. Aging 2006, 28:1075-1087.
35. Stoub T.R., Bulgakova M., Leurgans S., Bennett D.A., Fleischman D., Turner D.A., Toledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005, 64:1520-1524.
36. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23:159-169.
37. Szekely C.A., Green R.C., Breitner J.C., Ostbye T., Beiser A.S., Corrada M.M., Dodge H.H., Ganguli M., Kawas C.H., Kuller L.H., Psaty B.M., Resnick S.M., Wolf P.A., Zonderman A.B., Welsh-Bohmer K.A., Zandi P.P. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008, 70:2291-2298.
38. Szekely C.A., Breitner J.C., Fitzpatrick A.L., Rea T.D., Psaty B.M., Kuller L.H., Zandi P.P. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008, 70:17-24.
39. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell. Biol. 2005, 37:289-305.
40. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
41. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI) 1999, San Antonio, PsychCorp.
42. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
43. Wishart H.A., Saykin A.J., McAllister T.W., Rabin L.A., McDonald B.C., Flashman L.A., Roth R.M., Mamourian A.C., Tsongalis G.J., Rhodes C.H. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 2006, 67:1221-1224.